FCSC has been the topic of a number of other research reports. ValuEngine upgraded shares of Fibrocell Science from a strong sell rating to a sell rating in a research report on Thursday, June 15th. Zacks Investment Research upgraded shares of Fibrocell Science from a hold rating to a buy rating and set a $4.25 price objective on the stock in a research report on Wednesday, July 12th.
Shares of Fibrocell Science (NASDAQ FCSC) traded down 11.55% during mid-day trading on Wednesday, hitting $2.68. The stock had a trading volume of 106,204 shares. The firm’s 50 day moving average price is $3.61 and its 200 day moving average price is $2.24. The company’s market cap is $39.38 million. Fibrocell Science has a 1-year low of $0.52 and a 1-year high of $4.64.
Fibrocell Science (NASDAQ:FCSC) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.31). Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 293.07%. Analysts predict that Fibrocell Science will post ($1.39) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its position in shares of Fibrocell Science by 272.4% in the fourth quarter. Renaissance Technologies LLC now owns 194,000 shares of the company’s stock worth $122,000 after buying an additional 141,900 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of Fibrocell Science by 264.0% in the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after buying an additional 35,000 shares during the period. Finally, Creative Planning increased its position in shares of Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after buying an additional 48,755 shares during the period. Institutional investors own 55.31% of the company’s stock.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.